Sarah J. Ratcliffe

Sarah J. Ratcliffe

Auto-generated profile, based on publicly available information

Sarah J. Ratcliffe

University of Virginia, Charlottesville, VA, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2014 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
LYLichuan Ye
Lichuan Ye
GPGrace W. Pien
Grace W. Pien
SRSarah J. Ratcliffe
Sarah J. Ratcliffe
EBErla Björnsdottir
Erla Björnsdottir
Erna Sif ArnardóttirErna Sif Arnardóttir
Erna Sif Arnardóttir
TGThorarinn Gislason
Thorarinn Gislason
Although commonly observed in clinical practice, the heterogeneity of obstructive sleep apnoea (OSA) clinical presentation has not been formally characterised.This study was the first to apply cluster analysis to identify subtypes of patients with OSA who experience distinct combinations of symptoms and comorbidities. An analysis of baseline data from the Icelandic Sleep Apnoea Cohort (822 patients with newly diagnosed moderate-to-severe OSA) was performed.Three distinct clusters were identified. They were classified as the “disturbed sleep group” (cluster 1), “minimally symptomatic group” (cluster 2) and “excessive daytime sleepiness group” (cluster 3), consisting of 32.7%, 24.7% and 42.6% of the entire cohort, respectively. The probabilities of having comorbid hypertension and cardiovascular disease were highest in cluster 2 but lowest in cluster 3. The clusters did not differ significantly in terms of sex, body mass index or apnoea–hypopnoea index.Patients with OSA have different patterns of clinical presentation, which need to be communicated to both the lay public and the professional community with the goal of facilitating care-seeking and early identification of OSA. Identifying distinct clinical profiles of OSA creates a foundation for offering more personalised therapies in the future.

1 June 2009 in Pediatrics
Verified
Journal Article
Closed access
PDF file
CCChristina J. Calamaro
Christina J. Calamaro
TMThornton B. A. Mason
Thornton B. A. Mason
SRSarah J. Ratcliffe
Sarah J. Ratcliffe
OBJECTIVE. Adolescents may not receive the sleep they need. New media technology and new, popular energy drinks may be implicated in sleep deficits. In this pilot study we quantified nighttime technology use and caffeine consumption to determine effects on sleep duration and daytime behaviors in adolescents. We hypothesized that with increased technology use, adolescents increase caffeine consumption, resulting in insufficient sleep duration. PATIENTS AND METHODS. Subjects were recruited from a pediatric office in a proximal suburb of Philadelphia, Pennsylvania. Inclusion criteria for this study were middle and high school subjects aged 12 to 18 years old. The questionnaire, Adolescent Sleep, Caffeine Intake, and Technology Use, was developed by the investigators to measure adolescents' intake of caffeinated drinks, use of nighttime media-related technology, and sleep behaviors. Descriptive statistics characterized the subjects, their caffeine and technology use, and sleep variables. Regression models assessed the relationships between caffeine, technology use, and sleep variables, having adjusted for age, race, gender, and BMI. RESULTS. Sleep was significantly related to the multitasking index. Teenagers getting 8 to 10 hours of sleep on school nights tended to have 1.5- to 2-fold lower multitasking indices compared with those getting less sleep. Thirty-three percent of the teenagers reported falling asleep during school. Caffeine consumption tended to be 76% higher by those who fell asleep. The log-transformed multitasking index was significantly related to falling asleep during school and with difficulties falling asleep on weeknights. CONCLUSIONS. Many adolescents used multiple forms of technology late into the night and concurrently consumed caffeinated beverages. Subsequently, their ability to stay alert and fully functional throughout the day was impaired by excessive daytime sleepiness. Future studies should measure more than television hours when evaluating the impact of nighttime activities on sleep patterns in adolescents.

1 November 2005 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
GMGeorge A. Macones
George A. Macones
JPJeffrey Peipert
Jeffrey Peipert
DNDeborah B. Nelson
Deborah B. Nelson
AOAnthony Odibo
Anthony Odibo
ESErika J. Stevens
Erika J. Stevens
SRSarah J. Ratcliffe
Sarah J. Ratcliffe

1 January 2008 in Journal of Statistical Software
Verified
Journal Article
Open access
SRSarah J. Ratcliffe
Sarah J. Ratcliffe
JSJustine Shults
Justine Shults
GEEQBOX: A MATLAB Toolbox for Generalized Estimating Equations and Quasi-Least Squares

1 July 2009 in SLEEP
Verified
Journal Article
Open access
PDF file
ECEileen R. Chasens
Eileen R. Chasens
SRSarah J. Ratcliffe
Sarah J. Ratcliffe
TWTerri E. Weaver
Terri E. Weaver
The Functional Outcomes of Sleep Questionnaire (FOSQ), has been used in research and clinical practice to measure the impact of daytime sleepiness on activities of daily living. The purpose of this study was to develop a shorter version of the instrument (FOSQ-10) that may be more easily implemented in clinical practice. Data from a study of CPAP-treated obstructive sleep apnea (OSA) patients (Sample 1) (n = 155, AHI = 63 ± 31) were used to develop the FOSQ-10. Of the 30 original FOSQ items, 10 questions representing each of the 5 subscales were selected if they had a normal distribution of responses and the largest pre- to post-treatment effect size. The psychometric properties of the instrument were then evaluated with data from a second, independent sample of CPAP-treated OSA patients (n = 51 AH I = 51 ± 28). Internal consistency of the FOSQ-10 was α = 0.87. Pre-treatment correlations of the 2 scales was r = 0.96. After 3 months of treat- ment the correlation was r = 0.97 (P < 0.0001). Subscales were also highly correlated at baseline and following treatment. Effect sizes for both instruments were highly correlated and indicated ability to measure meaningful change. Differences were observed between scores on the FOSQ-10 for normal controls and OSA patients. The FOSQ-10 is a psychometrically strong instrument that performs similarly to the long version. The rapidly completed and easily scored FOSQ-10 shows promise for application in the clinical setting.

1 April 2012 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
SDSanjay Dixit
Sanjay Dixit
FMFrancis E. Marchlinski
Francis E. Marchlinski
DLDavid Lin
David Lin
DCDavid J. Callans
David J. Callans
RBRupa Bala
Rupa Bala
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
Background—: The single-procedure efficacy of pulmonary vein isolation (PVI) is less than optimal in patients with persistent atrial fibrillation (AF). Adjunctive techniques have been developed to enhance single-procedure efficacy in these patients. We conducted a study to compare 3 ablation strategies in patients with persistent AF. Methods and Results—: Subjects were randomized as follows: arm 1, PVI + ablation of non-PV triggers identified using a stimulation protocol (standard approach); arm 2, standard approach + empirical ablation at common non-PV AF trigger sites (mitral annulus, fossa ovalis, eustachian ridge, crista terminalis, and superior vena cava); or arm 3, standard approach + ablation of left atrial complex fractionated electrogram sites. Patients were seen at 6 weeks, 6 months, and 1 year; transtelephonic monitoring was performed at each visit. Antiarrhythmic drugs were discontinued at 3 to 6 months. The primary study end point was freedom from atrial arrhythmias off antiarrhythmic drugs at 1 year after a single-ablation procedure. A total of 156 patients (aged 59±9 years; 136 males; AF duration, 47±50 months) participated (arm 1, 55 patients; arm 2, 50 patients; arm 3, 51 patients). Procedural outcomes (procedure, fluoroscopy, and PVI times) were comparable between the 3 arms. More lesions were required to target non-PV trigger sites than a complex fractionated electrogram (33±9 versus 22±9; P <0.001). The primary end point was achieved in 71 patients and was worse in arm 3 (29%) compared with arm 1 (49%; P =0.04) and arm 2 (58%; P =0.004). Conclusions—: These data suggest that additional substrate modification beyond PVI does not improve single-procedure efficacy in patients with persistent AF. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00379301.